European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials47
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients46
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients43
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY41
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial40
Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)39
Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials35
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle34
Renal protection in chronic heart failure: focus on sacubitril/valsartan32
Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis31
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events30
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial29
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy29
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis28
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy28
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation26
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)26
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence26
What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions25
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines25
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?23
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease23
The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer23
0.086053133010864